NASDAQ · KYMR
Kymera Therapeutics, Inc.
$122.60+$0.09 (+0.07%)
Kymera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
Loading market information…
NASDAQ · CRNX · USD
Stock price, earnings
Quote as of Sep 1, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Crinetics Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.07% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Crinetics Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.20. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Crinetics Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$1.04-5.05% vs estimate | $361.00K+3.76% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -$0.88+4.35% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.96-5.42% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
21 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $85.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$122.60+$0.09 (+0.07%)
Kymera Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.73% below the high.
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
$29.64+$0.22 (+0.75%)
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
$54.65$0.00 (0.0%)
Akero Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.42% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
$20.76+$0.44 (+2.17%)
Acadia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.95% below the high.
$26.86+$1.50 (+5.91%)
Viking Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.75% below the high.
$17.04+$0.06 (+0.35%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
